EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
EyePoint Pharmaceuticals Inc
Research & Development
EyePoint Pharmaceuticals Inc
Research & Development Peer Comparison
Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors
Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
|
Research & Development
-$64.7m
|
CAGR 3-Years
-55%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-22%
|
|
Johnson & Johnson
NYSE:JNJ
|
Research & Development
-$15.2B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-6%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Research & Development
-$9.3B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-10%
|
|
Pfizer Inc
NYSE:PFE
|
Research & Development
-$10.6B
|
CAGR 3-Years
-74%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-5%
|
|
Merck & Co Inc
NYSE:MRK
|
Research & Development
-$29.5B
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-15%
|
|
Eli Lilly and Co
NYSE:LLY
|
Research & Development
-$9.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-6%
|
See Also
What is EyePoint Pharmaceuticals Inc's Research & Development?
Research & Development
-64.7m
USD
Based on the financial report for Dec 31, 2023, EyePoint Pharmaceuticals Inc's Research & Development amounts to -64.7m USD.
What is EyePoint Pharmaceuticals Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-22%
Over the last year, the Research & Development growth was -30%. The average annual Research & Development growth rates for EyePoint Pharmaceuticals Inc have been -55% over the past three years , -28% over the past five years , and -22% over the past ten years .